Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma

被引:46
作者
Lorello, G. [2 ]
la Porte, C. [1 ,2 ,3 ]
Pilon, R. [4 ]
Zhang, G. [3 ]
Karnauchow, T. [2 ,5 ]
MacPherson, P. [1 ,2 ,3 ,6 ]
机构
[1] Ottawa Hosp, Div Infect Dis, Ottawa, ON K1H 8L6, Canada
[2] Univ Ottawa, Fac Med, Ottawa, ON, Canada
[3] Ottawa Hlth Res Inst, Ottawa, ON, Canada
[4] Publ Hlth Agcy Canada, Ottawa, ON, Canada
[5] Childrens Hosp Eastern Ontario, Div Virol, Ottawa, ON K1H 8L1, Canada
[6] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada
基金
加拿大健康研究院;
关键词
antiretroviral concentrations; blood; HIV; semen; viral load; HUMAN-IMMUNODEFICIENCY-VIRUS; SEMINAL PLASMA; SEXUAL TRANSMISSION; RNA LEVELS; THERAPY; MEN; URETHRITIS; SECRETIONS; INFECTION; PROTEASE;
D O I
10.1111/j.1468-1293.2009.00725.x
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Objectives For individuals not on antiretroviral therapy, the risk of heterosexual transmission of HIV appears negligible when blood plasma (BP) viral loads are < 1500 HIV-1 RNA copies/mL. It is not clear whether this observation can be extrapolated to individuals on highly active antiretroviral therapy (HAART). Because of differential tissue penetration, antiretroviral drug concentrations may be sufficient to maintain an undetectable viral load in the BP yet not achieve adequate levels to suppress HIV in the genital tract. Therefore, we wanted to correlate HIV viral loads and drug concentrations in semen plasma (SP) and BP. Methods Thirty-three men were included. All were on combination antiretroviral therapy with an undetectable BP viral load for at least 1 year. Blood and semen samples were collected within 2 h of each other and tested for HIV RNA by the NucliSens QT (bioMerieux, St Laurent, QC, Canada) method; drug concentrations were determined by liquid chromatography tandem mass spectrometry. Results Two of the 33 patients (6.1%) with BP viral loads below detection had time-matched HIV viral loads in SP >= 700 copies/mL. Both patients were on efavirenz, the SP concentrations of which were < 10% of the levels in BP and well below the minimal therapeutic drug monitoring target concentration required to suppress HIV. Conclusions Because, at least in part, of poor drug penetration into the genital tract, an undetectable HIV viral load in the BP does not guarantee an undetectable viral load in semen. In view of this, caution should be taken in concluding that patients on HAART with suppressed viraemia are sexually non-infectious.
引用
收藏
页码:548 / 554
页数:7
相关论文
共 35 条
[1]
Adherence to antiretroviral therapy and persistence of HIV RNA in semen [J].
Barroso, PF ;
Schechter, M ;
Gupta, P ;
Bressan, C ;
Bomfim, A ;
Harrison, LH .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (04) :435-440
[2]
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes [J].
Bujan, L ;
Daudin, M ;
Matsuda, T ;
Righi, L ;
Thauvin, L ;
Berges, L ;
Izopet, J ;
Berrebi, A ;
Massip, P ;
Pasquier, C .
AIDS, 2004, 18 (05) :757-766
[3]
Early human immunodeficiency virus (HIV) infection in the HIV network for prevention trials vaccine preparedness cohort: Risk behaviors, symptoms, and early plasma and genital tract virus load [J].
Celum, CL ;
Buchbinder, SP ;
Donnell, D ;
Douglas, JM ;
Mayer, K ;
Koblin, B ;
Marmor, M ;
Bozeman, S ;
Grant, RM ;
Flores, J ;
Sheppard, HW .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (01) :23-35
[4]
Pathophysiology of HIV-1 in semen: Current evidence for compartmentalisation and penetration by antiretroviral drugs [J].
Chan, DJ .
CURRENT HIV RESEARCH, 2005, 3 (03) :207-222
[5]
Reduction of concentration of HIV-1, in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1 [J].
Cohen, MS ;
Hoffman, IF ;
Royce, RA ;
Kazembe, P ;
Dyer, JR ;
Daly, CC ;
Zimba, D ;
Vernazza, PL ;
Maida, M ;
Fiscus, SA ;
Eron, JJ ;
Nkata, E ;
Kachenje, E ;
Banda, T ;
Mughogho, G ;
Koller, C ;
Schock, J ;
Chakraborty, H ;
Dallabetta, G ;
Gilliam, B .
LANCET, 1997, 349 (9069) :1868-1873
[6]
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850) [J].
Eron, JJ ;
Smeaton, LM ;
Fiscus, SA ;
Gulick, RM ;
Currier, JS ;
Lennox, JL ;
D'Aquila, RT ;
Rogers, MD ;
Tung, R ;
Murphy, RL .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1622-1628
[7]
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies [J].
Fiore, JR ;
Suligoi, B ;
Saracino, A ;
Di Stefano, M ;
Bugarini, R ;
Lepera, A ;
Favia, A ;
Monno, L ;
Angarano, G ;
Pastore, G .
AIDS, 2003, 17 (15) :2169-2176
[8]
IMPACT OF IMPROVED TREATMENT OF SEXUALLY-TRANSMITTED DISEASES ON HIV-INFECTION IN RURAL TANZANIA - RANDOMIZED CONTROLLED TRIAL [J].
GROSSKURTH, H ;
MOSHA, F ;
TODD, J ;
MWIJARUBI, E ;
KLOKKE, A ;
SENKORO, K ;
MAYAUD, P ;
CHANGALUCHA, J ;
NICOLL, A ;
KAGINA, G ;
NEWELL, J ;
MUGEYE, K ;
MABEY, D ;
HAYES, R .
LANCET, 1995, 346 (8974) :530-536
[9]
High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors [J].
Gupta, P ;
Mellors, J ;
Kingsley, L ;
Riddler, S ;
Singh, MK ;
Schreiber, S ;
Cronin, M ;
Rinaldo, CR .
JOURNAL OF VIROLOGY, 1997, 71 (08) :6271-6275
[10]
Communication of HIV viral load to guide sexual risk decisions with serodiscordant partners among San Francisco men who have sex with men [J].
Guzman, R. ;
Buchbinder, S. ;
Mansergh, G. ;
Vittinghoff, E. ;
Marks, G. ;
Wheeler, S. ;
Colfax, G. N. .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2006, 18 (08) :983-989